8 085 Mg Of Ivabradine Hydrochloride

證據等級: L5

預測適應症: 0 個

Ivabradine: Evaluation Report — Insufficient Data for Repurposing Assessment

One-Sentence Summary

The Evidence Pack submitted contains a malformed drug entry ("8.085 MG OF IVABRADINE HYDROCHLORIDE)"), which appears to be a dosage descriptor incorrectly captured as an INN — the actual active ingredient is ivabradine (a selective funny current Ih inhibitor used in heart failure and stable angina). No TxGNN-predicted indications were returned for this entry, and Singapore regulatory registration records are absent. As a result, a full repurposing evaluation cannot be completed; the data gaps below must be resolved before assessment can proceed.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	None returned by TxGNN
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — and none present)
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why This Report Cannot Be Completed

The Evidence Pack contains a critical data quality issue at the drug identification stage:

Problem — Malformed INN field: The drug.inn field contains "8.085 MG OF IVABRADINE HYDROCHLORIDE)" — a dosage strength descriptor, not an INN. This string is the declared content of one Procoralan/Corlentor film-coated tablet (8.085 mg ivabradine hydrochloride = 7.5 mg ivabradine base). The upstream data pipeline appears to have concatenated the dosage line into the ingredient name field during parsing.

Downstream consequences:

The DDI query returned no results (the malformed string matched no known drug)
DrugBank returned 1 result (likely a partial fuzzy match), but no drugbank_id was stored
No original indications were extracted
No predicted indications were generated — predicted_indications is an empty array
All safety fields are [Data Gap]

Because predicted_indications is empty, the sections for Why is This Prediction Reasonable, Clinical Trial Evidence, Literature Evidence, Cytotoxicity, and Conclusion and Next Steps cannot be populated with evidence-based content.

Singapore Market Information

No registered products found for this entry.

Based on international data, ivabradine is marketed globally as Procoralan (Servier) and Corlanor (Amgen/US). If ivabradine is correctly identified and re-queried, Singapore HSA registration records should be searched under the INN ivabradine or brand name Procoralan.

Safety Considerations

Please refer to the package insert for safety information. No safety data was retrievable for this malformed drug entry.

Conclusion and Next Steps

Decision: Hold

Rationale: The drug entry is structurally invalid — the INN field contains a dosage string rather than a drug name, which has propagated as a data error through every downstream pipeline stage, resulting in zero predicted indications and zero safety data.

To proceed, the following is needed:

Fix the data pipeline — identify the upstream parsing step that merged dosage text into the INN field, and correct the record so that drug.inn = "ivabradine" (or "ivabradine hydrochloride")
Re-run TxGNN prediction against the corrected INN to obtain predicted_indications
Re-query DrugBank with ivabradine to retrieve drugbank_id, original_moa, and toxicity data
Re-query Singapore HSA with the corrected drug name to populate taiwan_regulatory fields
Re-query DDI database with ivabradine to retrieve interaction data
Once all above are resolved, resubmit a corrected Evidence Pack for a complete L1–L5 repurposing evaluation

⚠️ Data Quality Note: This report was generated from an Evidence Pack with a Blocking data gap (DG001) and a High-severity gap (DG002). The drug INN field contains a dosage descriptor rather than a valid drug name, rendering all downstream predictions and safety lookups invalid. No clinical or regulatory conclusions should be drawn from this report.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.